January 2008
Worldwide Biotech;Jan2008, Vol. 20 Issue 1, p2
Trade Publication
The article reports on a marketing authorization application filed by Merck & Co. Inc. with the European Medicines Agency (EMEA) for vorinostat for the treatment of advanced, refractory cutaneous T-cell lymphoma (CTCL) in the European Union. If the application is approved, Merck will be allowed to market the product in all 27 Member States in the European Union, as well as Iceland and Norway.


Related Articles

  • Feds subpoena Merck on 3 drugs. M. I. // Medical Marketing & Media;Sep2011, Vol. 46 Issue 9, p10 

    The article reports that Merck & Co. Inc. in the U.S. has received a subpoena related to marketing and selling activities with respect to three drugs namely Temodar, PegIntron and Intron A.

  • West Point steps out.  // Drug Topics;5/23/94, Vol. 138 Issue 10, p64 

    Reports on West Point Pharma's plans for expanding its generic drug line by marketing generic versions of off-patent drugs originated by pharmaceutical companies other than Merck.

  • State wins case against Merck. Jacklet, Ben // Oregon Business Magazine;Jul2008, Vol. 31 Issue 7, p20 

    The article reports that Oregon has received more than $8.5 million on winning a court case against Merck & Co. over deceptive marketing for the drug Vioxx. The state lead a three-year investigation into Merck's deceptive advertisements downplaying the health risks associated with Vioxx. The...

  • Merck Lesson: Risk Needs Rebranding. Edwards, Jim // Brandweek;11/7/2005, Vol. 46 Issue 40, p22 

    Discusses the issues surrounding the victory of pharmaceutical firm Merck during the trial filed against it for marketing the drug Vioxx in 2005. Lessons learned from the trial; Effect of the trial on the U.S. pharmaceutical industry; Efforts of several pharmaceutical firms to restore the faith...

  • Merck, Dow Scolded Over Promotions.  // BioWorld Today;3/12/2012, Vol. 23 Issue 48, p4 

    The article reports on the reminder given by the U.S. Food and Drug Administration (FDA) to Dow Pharmaceuticals Sciences Inc. and Merck and Co. Inc. that letters from the FDA Office of Prescription Drug Promotion (OPDP) urge them to task over their drug promotions.

  • Zetia Avoids the Noise. Breitstein, Joanna // Pharmaceutical Executive;Jan2003, Vol. 23 Issue 1, p67 

    Reports on the decision of the Merck/Schering-Plough joint venture to focus its marketing efforts for its hyperlipidemia product Zetia or ezetimibe on physician promotion in the United States. Reason why the joint venture decided against running consumer advertisement for its hyperlipidemia...

  • Drugmakers put cash into apps, education websites.  // Medicine on the Net;Apr2011, Vol. 17 Issue 4, p6 

    The article reports on the investments made by drug companies led by Merck & Co. Inc. and Novartis AG in mobile phone applications and educational websites for patients to take their drugs, eat right and exercise.

  • No direct-to-consumer drug ads: CMA. Sullivan, Patrick // CMAJ: Canadian Medical Association Journal;11/12/2002, Vol. 167 Issue 10, p1153 

    Reports the Canadian Medical Association (CMA) opposes the use of direct-to-consumer (DTC) advertising of prescription drugs in Canada. Indications of successful DTC advertising in United States including the marketing of Vioxx by Merck; Opinions offered by CMA that DTC advertising may not...

  • Health growth. Hewitt, Allison // Pharmaceutical Executive;Oct97, Vol. 17 Issue 10, p112 

    Reports that Corbett HealthConnect has been named agency of record for all professional promotions for Crixivan, Merck & Co.'s leading HIV/AIDS protease inhibitor in the United States.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics